U.S. Markets closed
  • S&P Futures

    4,409.00
    -6.00 (-0.14%)
     
  • Dow Futures

    34,960.00
    -38.00 (-0.11%)
     
  • Nasdaq Futures

    15,034.75
    -11.50 (-0.08%)
     
  • Russell 2000 Futures

    2,213.80
    -5.60 (-0.25%)
     
  • Crude Oil

    70.20
    -0.36 (-0.51%)
     
  • Gold

    1,812.50
    -1.60 (-0.09%)
     
  • Silver

    25.58
    -0.00 (-0.01%)
     
  • EUR/USD

    1.1869
    +0.0001 (+0.0119%)
     
  • 10-Yr Bond

    1.1760
    +0.0020 (+0.17%)
     
  • Vix

    18.04
    -1.42 (-7.30%)
     
  • GBP/USD

    1.3913
    -0.0002 (-0.0167%)
     
  • USD/JPY

    108.9600
    -0.0900 (-0.0825%)
     
  • BTC-USD

    38,480.54
    -547.42 (-1.40%)
     
  • CMC Crypto 200

    939.41
    -4.03 (-0.43%)
     
  • FTSE 100

    7,105.72
    +24.00 (+0.34%)
     
  • Nikkei 225

    27,542.67
    -99.16 (-0.36%)
     

Ampio Pharma's Inhaled COVID-19 Treatment Shows 78% Improvement In All-Cause Mortality

·1 min read
  • Ampio Pharmaceuticals Inc (NYSE: AMPE) revealed positive results from its AP-014 Phase 1 trial utilizing inhaled Ampion in treating respiratory distress in COVID-19 patients.

  • The study met its primary endpoint and showed an even greater improvement in all-cause mortality over patients treated using Standard of Care (SOC) than initially reported.

  • Mortality in the SOC group was 24%, while that in the group treated with SOC and Ampion was only 5%,

  • Preliminary results reported in March showed a lower all-cause mortality rate of 8% in the Ampion group, compared to 21% in the standard of care alone.

  • The average hospital length of stay was four days less for the Ampion group than the patients receiving SOC.

  • Separately, the Phase 1 study using Ampion to address the respiratory symptoms experienced by COVID-19 "Long Haulers" is awaiting Investigational Review Board approval and is expected to commence enrollment shortly.

  • Ampio also received a positive response from the FDA on its plans for its Phase 3 trial utilizing intra-articular injection of Ampion for treating osteoarthritis of the knee.

  • The company will provide updates on its plans for this trial at its upcoming May 5th earnings call.

  • Price Action: AMPE shares are down 3.2% at $1.93 in market trading hours on the last check Tuesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.